Agents that block the action of specific cytokines have changed the lives of many patients with rheumatoid arthritis and other autoimmune disorders. But frequent self-injections or injections by a physician during a clinic visit are required. Now a new class of anti-cytokine that may bypass such problems appears on the horizon (pages 47–52).
This is a preview of subscription content, log in via an institution to check access.
Courtesy of E. Koehler-Stec, T. Sterlacci and S. Staton
References
Economides, A.N. et al. Cytokine traps: Multi-component, high-affinity blockers of cytokine action. Nature Med. 9, 47–52 (2003).
Stahl, N. & Yancopoulos, G.D. The alphas, betas, and kinases of cytokine receptor complexes. Cell 74, 587–590 (1993).
Frishman, J.I. et al. Tumor necrosis factor (TNF)-α-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. J. Infect. Dis. 182, 1722–1730 (2000).
Preas, H.L., 2nd et al. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood 88, 2465–2472 (1996).
Moreland, L.W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141–147 (1997).
Fleischman, R. et al. A safety trial of anakinra: Recombinant interleukin-1 receptor antagonist in a large, placebo controlled heterogenous population of patients with rheumatoid arthritis. Arthrit. Rheumat. (in the press).
Bresnihan, B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthrit. Rheum. 41, 2196–2204 (1998).
Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α-neutralizing agent. N. Engl. J. Med. 345, 1098–1104 (2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dinarello, C. Setting the cytokine trap for autoimmunity. Nat Med 9, 20–22 (2003). https://doi.org/10.1038/nm0103-20
Issue Date:
DOI: https://doi.org/10.1038/nm0103-20
- Springer Nature America, Inc.
This article is cited by
-
Involvement of inflammasomes in tumor microenvironment and tumor therapies
Journal of Hematology & Oncology (2023)
-
Creating a Soluble Binder to Endothelin-1 Based on the Natural Ligand Binding Domains of the Endothelin-1 (G-Protein-Coupled) Receptor
International Journal of Peptide Research and Therapeutics (2019)
-
Helicobacter pylori-induced IL-33 modulates mast cell responses, benefits bacterial growth, and contributes to gastritis
Cell Death & Disease (2018)
-
Setting a trap for cytokines
Nature Reviews Drug Discovery (2003)